uniQure N.V. - QURE STOCK NEWS

uniQure (Nasdaq: QURE) has announced the pricing of its public offering of 4,411,764 ordinary shares at $17.00 per share, expecting to raise approximately $75 million in gross proceeds before deducting underwriting costs and expenses. The company has also granted underwriters a 30-day option to purchase up to 661,764 additional shares at the same price.

The offering is expected to close around January 10, 2025. Leerink Partners, Stifel, and Guggenheim Securities are serving as bookrunning managers, while Chardan and H.C. Wainwright & Co. are acting as lead managers for the offering. The shares are being offered through an automatically effective shelf registration statement filed with the SEC on January 7, 2025.

uniQure (Nasdaq: QURE) has announced the launch of an underwritten public offering of ordinary shares and pre-funded warrants to purchase ordinary shares. The gene therapy company plans to grant underwriters a 30-day option to purchase up to an additional 15% of ordinary shares at the public offering price, less underwriting discounts and commissions.

Leerink Partners is serving as the bookrunning manager for the proposed offering. The securities will be offered through an automatically effective shelf registration statement on Form S-3 filed with the SEC on January 7, 2025. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

uniQure has reached an agreement with the FDA on key elements for an Accelerated Approval pathway for AMT-130, their Huntington's disease treatment. The FDA agreed that data from ongoing Phase I/II studies compared to natural history external control can serve as the primary basis for a Biologics License Application (BLA), eliminating the need for additional pre-submission studies.

The FDA accepted the composite Unified Huntington's Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint and acknowledged that reductions in neurofilament light chain (NfL) in cerebrospinal fluid may support evidence of therapeutic benefit. This follows the RMAT designation granted in May 2024 and promising interim data from July 2024 showing durable, dose-dependent slowing of disease progression.

uniQure has announced the dosing of the first patient in its GenTLE Phase I/IIa clinical trial of AMT-260, targeting refractory mesial temporal lobe epilepsy (MTLE). The trial evaluates a one-time gene therapy treatment using an AAV9 vector that delivers engineered miRNAs to reduce GluK2 protein expression, which is believed to trigger seizures in MTLE patients. The study will include two dose cohorts of six patients each across 10 active sites, with two additional sites planned by end of 2024. Preclinical studies showed AMT-260 reduced seizure frequency in a dose-dependent manner and decreased GluK2 expression in both animal models and patient tissue samples.

uniQure reported Q3 2024 financial results with a strong cash position of $435.2 million, extending runway through 2027. The company announced positive interim data from AMT-130 trials in Huntington's disease, showing significant disease progression slowing. A Type B FDA meeting is scheduled for Q4 2024 to discuss potential expedited development. The company initiated patient dosing in new Phase I/II studies for SOD1-ALS and Fabry disease treatments.

Q3 net loss was $44.4 million ($0.91 per share), improved from $89.6 million loss in Q3 2023. The company completed organizational restructuring, including the sale of its Lexington facility, expected to reduce annual cash burn by $70 million and eliminate 65% of roles.

uniQure N.V. (NASDAQ: QURE) has announced the dosing of the first patient in the Phase I/II clinical trial of AMT-162 for the treatment of SOD1-ALS, a rare inherited form of amyotrophic lateral sclerosis. The EPISOD1 trial is a multi-center, open-label study with three dose-escalating cohorts, designed to assess the safety, tolerability, and exploratory efficacy of AMT-162.

AMT-162 is an AAVrh10-based gene therapy that aims to knock down the expression of mutated SOD1 protein, which is toxic to motor neurons. The therapy, administered intrathecally as a one-time treatment, has received Orphan Drug status and Fast Track designation from the FDA.

The trial will be conducted in the United States, with four active sites and plans to activate seven more by Q1 2025. It will measure neurofilament light chain and SOD1 protein levels as exploratory efficacy markers.

uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce GLA protein.

The Phase I/IIa trial will include two cohorts of up to six adult male patients each, with low and high doses. Patients will be followed for 24 months to assess safety, tolerability, and early efficacy signs. The Orphan Drug Designation provides incentives including tax credits, grants, fee waivers, and seven years of market exclusivity upon approval.

uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry disease treatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the liver. It aims to address the α-galactosidase A enzyme deficiency in Fabry patients.

The trial includes two cohorts of up to six adult male patients each, with low (6x10^13 gc/kg) and high (3x10^14 gc/kg) doses administered intravenously. Patients will be followed for 24 months. This milestone aligns with uniQure's goal to advance three new gene therapies into clinical studies this year, alongside programs in Huntington's disease, temporal lobe epilepsy, and SOD1-ALS.

uniQure (NASDAQ: QURE) reported its Q2 2024 financial results and provided a company update. Key highlights include:

1. RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data showing slowing of disease progression.

2. Initiated patient screening for three Phase I/II studies in epilepsy, ALS, and Fabry disease.

3. Announced organizational restructuring, reducing headcount by 65% and lowering cash burn by $75 million annually.

4. Strong cash position of $524 million as of June 30, 2024, expected to fund operations through 2027.

5. Q2 2024 revenue of $11.1 million, up from $2.4 million in Q2 2023.

6. Net loss of $56.3 million ($1.16 per share) in Q2 2024, compared to $68.5 million ($1.44 per share) in Q2 2023.